中医药治疗克罗恩病的疗效:系统回顾与元分析》。

Michael L Chang, Kaitlyn L Mi, Rachel R Cunningham, William A Catterall, Mahlet A Yared, Corey A Siegel, Renata W Yen
{"title":"中医药治疗克罗恩病的疗效:系统回顾与元分析》。","authors":"Michael L Chang, Kaitlyn L Mi, Rachel R Cunningham, William A Catterall, Mahlet A Yared, Corey A Siegel, Renata W Yen","doi":"10.15403/jgld-5729","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Crohn's disease (CD) is an inflammatory bowel disease with limited treatment options for patients with mild to moderately active disease. There is a lack of consensus for using traditional Chinese medicine (TCM) for symptom relief. This review aimed to assess the efficacy of TCM compared to placebo for CD symptom severity relief in patients with mild to moderate CD.</p><p><strong>Methods: </strong>We searched MEDLINE via PubMed, the Cochrane Library, Scopus, and CINAHL for articles and reviewed results from Web of Science, Google Scholar, clinicaltrials.gov, and reference lists of included studies. We included randomized control trials comparing TCM to placebo in patients with mild to moderate CD to evaluate change in objective symptom severity [Crohn's Disease Activity Index (CDAI) and Crohn's Disease Endoscopic Index of Severity (CDEIS)]. We imported selected articles for dual blinded review, used random-effects models to calculate the mean CDAI and CDEIS differences between TCM and placebo, and qualitatively analyzed differences in inflammatory biomarkers and quality of life.</p><p><strong>Results: </strong>The search identified 232 relevant studies. We included five studies, totalling 292 participants utilizing acupuncture and herb-partitioned moxibustion. The studies demonstrated a more significant decrease in mean CDAI score due to TCM compared to placebo [-49.91 (95% CI: -64.97, -34.84; p<0.00001); (I2 = 61%, p=0.03)]. Two studies also demonstrated an overall difference in mean CDEIS between TCM and placebo [-2.96 (95% CI: -6.31, 0.40; p=0.08); (I2 = 53%, p=0.140)]. Improvements in quality of life scores were greater in TCM versus placebo groups. There were mixed results for changes in inflammatory biomarkers.</p><p><strong>Conclusion: </strong>Our findings suggest that TCM may improve objective CD symptoms compared to placebo. Additional studies with more extensive and diverse populations are necessary to determine TCM's true effects on CD patients.</p>","PeriodicalId":94081,"journal":{"name":"Journal of gastrointestinal and liver diseases : JGLD","volume":"34 1","pages":"98-107"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Efficacy of Traditional Chinese Medicine for Crohn's Disease Treatment: A Systematic Review and Meta-Analysis.\",\"authors\":\"Michael L Chang, Kaitlyn L Mi, Rachel R Cunningham, William A Catterall, Mahlet A Yared, Corey A Siegel, Renata W Yen\",\"doi\":\"10.15403/jgld-5729\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aims: </strong>Crohn's disease (CD) is an inflammatory bowel disease with limited treatment options for patients with mild to moderately active disease. There is a lack of consensus for using traditional Chinese medicine (TCM) for symptom relief. This review aimed to assess the efficacy of TCM compared to placebo for CD symptom severity relief in patients with mild to moderate CD.</p><p><strong>Methods: </strong>We searched MEDLINE via PubMed, the Cochrane Library, Scopus, and CINAHL for articles and reviewed results from Web of Science, Google Scholar, clinicaltrials.gov, and reference lists of included studies. We included randomized control trials comparing TCM to placebo in patients with mild to moderate CD to evaluate change in objective symptom severity [Crohn's Disease Activity Index (CDAI) and Crohn's Disease Endoscopic Index of Severity (CDEIS)]. We imported selected articles for dual blinded review, used random-effects models to calculate the mean CDAI and CDEIS differences between TCM and placebo, and qualitatively analyzed differences in inflammatory biomarkers and quality of life.</p><p><strong>Results: </strong>The search identified 232 relevant studies. We included five studies, totalling 292 participants utilizing acupuncture and herb-partitioned moxibustion. The studies demonstrated a more significant decrease in mean CDAI score due to TCM compared to placebo [-49.91 (95% CI: -64.97, -34.84; p<0.00001); (I2 = 61%, p=0.03)]. Two studies also demonstrated an overall difference in mean CDEIS between TCM and placebo [-2.96 (95% CI: -6.31, 0.40; p=0.08); (I2 = 53%, p=0.140)]. Improvements in quality of life scores were greater in TCM versus placebo groups. There were mixed results for changes in inflammatory biomarkers.</p><p><strong>Conclusion: </strong>Our findings suggest that TCM may improve objective CD symptoms compared to placebo. Additional studies with more extensive and diverse populations are necessary to determine TCM's true effects on CD patients.</p>\",\"PeriodicalId\":94081,\"journal\":{\"name\":\"Journal of gastrointestinal and liver diseases : JGLD\",\"volume\":\"34 1\",\"pages\":\"98-107\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of gastrointestinal and liver diseases : JGLD\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15403/jgld-5729\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of gastrointestinal and liver diseases : JGLD","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15403/jgld-5729","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:克罗恩病(Crohn's disease,CD)是一种炎症性肠病,轻度至中度活动期患者的治疗方案有限。对于使用传统中药(TCM)缓解症状,目前尚缺乏共识。本综述旨在评估中药与安慰剂相比对缓解轻度至中度 CD 患者 CD 症状严重程度的疗效:我们通过 PubMed、Cochrane Library、Scopus 和 CINAHL 在 MEDLINE 上检索文章,并从 Web of Science、Google Scholar、clinicaltrials.gov 和纳入研究的参考文献列表中查阅结果。我们纳入了在轻度至中度 CD 患者中比较中药与安慰剂的随机对照试验,以评估客观症状严重程度[克罗恩病活动指数(CDAI)和克罗恩病内镜下严重程度指数(CDEIS)]的变化。我们导入了部分文章进行双盲审查,使用随机效应模型计算了中药与安慰剂之间的平均 CDAI 和 CDEIS 差异,并定性分析了炎症生物标志物和生活质量的差异:结果:搜索发现了 232 项相关研究。我们纳入了五项研究,共有 292 人参与了针灸和中草药隔物灸。这些研究表明,与安慰剂相比,中药能更显著地降低 CDAI 平均得分[-49.91 (95% CI: -64.97, -34.84; pConclusion]:我们的研究结果表明,与安慰剂相比,中药可改善 CD 的客观症状。要确定中药对 CD 患者的真正疗效,还需要对更广泛、更多样的人群进行更多研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Efficacy of Traditional Chinese Medicine for Crohn's Disease Treatment: A Systematic Review and Meta-Analysis.

Background and aims: Crohn's disease (CD) is an inflammatory bowel disease with limited treatment options for patients with mild to moderately active disease. There is a lack of consensus for using traditional Chinese medicine (TCM) for symptom relief. This review aimed to assess the efficacy of TCM compared to placebo for CD symptom severity relief in patients with mild to moderate CD.

Methods: We searched MEDLINE via PubMed, the Cochrane Library, Scopus, and CINAHL for articles and reviewed results from Web of Science, Google Scholar, clinicaltrials.gov, and reference lists of included studies. We included randomized control trials comparing TCM to placebo in patients with mild to moderate CD to evaluate change in objective symptom severity [Crohn's Disease Activity Index (CDAI) and Crohn's Disease Endoscopic Index of Severity (CDEIS)]. We imported selected articles for dual blinded review, used random-effects models to calculate the mean CDAI and CDEIS differences between TCM and placebo, and qualitatively analyzed differences in inflammatory biomarkers and quality of life.

Results: The search identified 232 relevant studies. We included five studies, totalling 292 participants utilizing acupuncture and herb-partitioned moxibustion. The studies demonstrated a more significant decrease in mean CDAI score due to TCM compared to placebo [-49.91 (95% CI: -64.97, -34.84; p<0.00001); (I2 = 61%, p=0.03)]. Two studies also demonstrated an overall difference in mean CDEIS between TCM and placebo [-2.96 (95% CI: -6.31, 0.40; p=0.08); (I2 = 53%, p=0.140)]. Improvements in quality of life scores were greater in TCM versus placebo groups. There were mixed results for changes in inflammatory biomarkers.

Conclusion: Our findings suggest that TCM may improve objective CD symptoms compared to placebo. Additional studies with more extensive and diverse populations are necessary to determine TCM's true effects on CD patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信